Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies

Clinics in Dermatology

Volumn 28, Issue 1, 2010, Pages 52-56

  Thaçi, Diamant ^a   Salgo, Rebekka ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; GLUCOCORTICOID; PIMECROLIMUS; TACROLIMUS;

ARTICLE; ATOPIC DERMATITIS; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HIGH RISK POPULATION; HUMAN; LYMPHOMA; MALIGNANT TRANSFORMATION; MOLECULAR WEIGHT; MULTIPLE CYCLE TREATMENT; NONHUMAN; OFF LABEL DRUG USE; ORGAN TRANSPLANTATION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SKIN CANCER; SKIN CARCINOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

ADMINISTRATION, TOPICAL; ANIMALS; CALCINEURIN; DERMATITIS, ATOPIC; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; RISK FACTORS; SKIN NEOPLASMS; TACROLIMUS;

EID: 71749089410     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2009.04.001     Document Type: Article

References (36)

1. Chairman C.R., and Williams H.C. Epidemiology. In: Bieber T., and Leung D. (Eds). Atopic dermatitis (2002), Marcel Dekker Inc, New York 21-42
2. Hinz T., Staudacher A., and Bieber T. Neues in der Pathophysiologie der atopischen Dermatitis. Hautarzt 7 (2006) 567-575
3. Fivenson D., Arnold R.J., Kaniecki D.J., Cohen J.L., Frech F., and Finlay A.Y. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm 8 (2002) 333-342
4. Bieber T., Cork M., Ellis C., et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 211 (2005) 77-78
5. Novartis and Fujisawa. FDA briefing statements. Pediatric Advisory Committee Meeting of the US Food and Drug Administration. Washington DC, 2005.
6. Wang H., and Diepgen T.L. Atopic dermatitis and cancer risk. Br J Dermatol 154 (2006) 205-210
7. Ming M.E., Levy R., Hoffstad O., et al. The lack of a relationship between atopic dermatitis and nonmelanoma skin cancers. J Am Acad Dermatol 50 (2004) 357-362
8. Sørensen H.T., Mellemkjaer L., Nielsen G.L., et al. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 96 (2004) 709-711
9. Hagstroemer L., Ye W., Nyren O., et al. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol 141 (2005) 1123-1127
10. Yarosh D.B., Pena A.V., Nay S.L., et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 125 (2005) 1020-1025
11. Hultsch T., Kapp A., and Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 211 (2005) 174-187
12. Bos J.D. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. Eur J Dermatol 13 (2003) 455-461
13. Van Leent E.J., Ebelin M.E., Burtin P., et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 204 (2002) 63-68
14. Paul C, Cork M., Rossi A.B., et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 117 (2006) e118-e128
15. Patel R.R., Vander Straten M.R., and Korman N.J. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol 139 (2003) 1184-1186
16. Alaiti S., Kang S., Fiedler V.C., et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 38 (1998) 69-76
17. Harper J., Smith C., Rubins A., et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 124 (2005) 695-699
18. Rubins A., Gutmane R., Valdmane N., et al. Pharmacokinetics of 0,1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol 125 (2005) 68-71
19. Eichenfield L.F., Thaçi D., de Prost Y., et al. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients. Dermatology 215 Suppl 1 (2007) 3-17
20. Thaçi D., Steinmeyer K., Ebelin M.E., et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology 207 (2003) 37-42
21. Spergel J.M., and Leung D.Y. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep 6 (2006) 270-274
22. Ormerod A.D. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?. Br J Dermatol 153 (2005) 701-705
23. Arellano F.M., Wentworth C.E., Arana A., et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 127 (2007) 808-816
24. Söderberg K.C., Hagmar L., Schwarztbaum J., et al. Allergic conditions and risk of haematological malignancies in adults: a cohort study. BMC Public Health 4 (2004) 51
25. Zhang Y., Holford T.R., Leaderer B., et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15 (2004) 419-428
26. Berger T.G., Duvic M., Van Voorhees A.S., et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. J Am Acad Dermatol 54 (2006) 818-823
27. Margolis D.J., Hoffstad O., and Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 214 (2007) 289-295
28. Lerche C.M., Philipsen P.A., Poulsen T., et al. Topical tacrolimus in combination with stimulated solar radiation does not enhance photocarcinogenesis in hairless mice. Exp Dermatol 17 (2008) 57-62
29. Beck L.A. The efficacy and safety of tacrolimus ointment: a clinical review. J Am Acad Dermatol 53 (2005) S165-S170
30. Becker J.C., Houben R., Vetter C.S., et al. The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer 6 (2006) 7
31. Ring J., Möhrenschlager M., and Henkel V. The US FDA "black box" warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 31 (2008) 185-198
32. Patel T.S., Greer S.C., and Skinner R.B. Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. Am J Clin Dermatol 8 (2007) 189-194
33. Luger T.A., and Gollnick H. Viewpoint of the German Dermatologic Society (DDG) concerning the decision of the American Food and Drug Administration (FDA) on the use of pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis (neurodermatitis). J Dtsch Dermatol Ges 3 (2005) 415-416
34. Fonacier L., Charlesworth E.N., Spergel J.M., and Leung D.Y. The black box warning for topical calcineurin inhibitors: looking outside the box. Ann Allergy Asthma Immunol 97 (2006) 117-120
35. Thaçi D., Reitamo S., Gonzalez Ensenat M.A., et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 159 (2008) 1348-1356
36. Qureshi A.A., and Fischer M.A. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risk. Arch Dermatol 142 (2006) 633-671